Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024))

Christophe Massard; Kim Nguyen Chi; Daniel Castellano; Johann de Bono; Gwenaelle Gravis; Luc Dirix; Jean Pascal Machiels; Alain Mita; Begoña Mellado; Sabine Turri; Joan Maier; Denes Csonka; Arunava Chakravartty; Karim Fizazi

doi:10.1016/j.ejca.2017.05.003

Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024))

Christophe Massard, Kim Nguyen Chi, Daniel Castellano, Johann de Bono, Gwenaelle Gravis, Luc Dirix, Jean Pascal Machiels, Alain Mita, Begoña Mellado, Sabine Turri, Joan Maier, Denes Csonka, Arunava Chakravartty, Karim Fizazi

Résultats de recherche: Contribution à un journal › !!Comment/debate

2 Citations (Scopus)

Résumé

The authors regret that the name of the 9th author was misspelt in the original publication. The correct spelling is Begoña Mellado, as given above. The authors would like to apologise for any inconvenience caused.

langue originale	Anglais
Pages (de - à)	242
Nombre de pages	1
journal	European Journal of Cancer
Volume	81
Les DOIs	https://doi.org/10.1016/j.ejca.2017.05.003
état	Publié - 1 août 2017

Accès au document

10.1016/j.ejca.2017.05.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Massard, C., Chi, K. N., Castellano, D., de Bono, J., Gravis, G., Dirix, L., Machiels, J. P., Mita, A., Mellado, B., Turri, S., Maier, J., Csonka, D., Chakravartty, A., & Fizazi, K. (2017). Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024)). European Journal of Cancer, 81, 242. https://doi.org/10.1016/j.ejca.2017.05.003

Massard, Christophe ; Chi, Kim Nguyen ; Castellano, Daniel et al. / Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024)). Dans: European Journal of Cancer. 2017 ; Vol 81. p. 242.

@article{b8c34134b1eb467ea9c2a3e95127b28b,

title = "Corrigendum to {\textquoteleft}Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer{\textquoteright} [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024))",

abstract = "The authors regret that the name of the 9th author was misspelt in the original publication. The correct spelling is Bego{\~n}a Mellado, as given above. The authors would like to apologise for any inconvenience caused.",

author = "Christophe Massard and Chi, {Kim Nguyen} and Daniel Castellano and {de Bono}, Johann and Gwenaelle Gravis and Luc Dirix and Machiels, {Jean Pascal} and Alain Mita and Bego{\~n}a Mellado and Sabine Turri and Joan Maier and Denes Csonka and Arunava Chakravartty and Karim Fizazi",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = aug,

day = "1",

doi = "10.1016/j.ejca.2017.05.003",

language = "English",

volume = "81",

pages = "242",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Massard, C, Chi, KN, Castellano, D, de Bono, J, Gravis, G, Dirix, L, Machiels, JP, Mita, A, Mellado, B, Turri, S, Maier, J, Csonka, D, Chakravartty, A & Fizazi, K 2017, 'Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024))', European Journal of Cancer, VOL. 81, p. 242. https://doi.org/10.1016/j.ejca.2017.05.003

Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024)). / Massard, Christophe; Chi, Kim Nguyen; Castellano, Daniel et al.
Dans: European Journal of Cancer, Vol 81, 01.08.2017, p. 242.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024))

AU - Massard, Christophe

AU - Chi, Kim Nguyen

AU - Castellano, Daniel

AU - de Bono, Johann

AU - Gravis, Gwenaelle

AU - Dirix, Luc

AU - Machiels, Jean Pascal

AU - Mita, Alain

AU - Mellado, Begoña

AU - Turri, Sabine

AU - Maier, Joan

AU - Csonka, Denes

AU - Chakravartty, Arunava

AU - Fizazi, Karim

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The authors regret that the name of the 9th author was misspelt in the original publication. The correct spelling is Begoña Mellado, as given above. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the name of the 9th author was misspelt in the original publication. The correct spelling is Begoña Mellado, as given above. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85020394413&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.05.003

DO - 10.1016/j.ejca.2017.05.003

M3 - Comment/debate

C2 - 28606464

AN - SCOPUS:85020394413

SN - 0959-8049

VL - 81

SP - 242

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L et al. Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024)). European Journal of Cancer. 2017 août 1;81:242. doi: 10.1016/j.ejca.2017.05.003